Logo

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Share this
Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Shots:

  • The company initiates P-III clinical trial to evaluate the efficacy- safety- tolerability- PK- and immunogenicity of SB17 vs Stelara in a ratio (1:1) in patients with moderate to severe plaque psoriasis
  • Additionally- patients either continue on Stelara or transition to SB17 @28wks. The IPs (SB17 or Stelara- q12w) will be administered @0- 4 and for up to 40wks. and the last assessment will be performed @52wks.
  • The company continues to advance a broad pipeline of biosimilar candidates covering therapeutic areas- including immunology- oncology- ophthalmology- hematology- endocrinology- and gastroenterology

Ref:  Samsung Bioepis | Image: PR Newswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions